Treventis develops small-molecule medicines that prevent disease-causing proteins from misfolding and forming toxic aggregates. Its patented Common Conformational Morphology discovery platform combines computational models of misfolded proteins with laboratory and animal testing to identify druggable sites. A tau oligomer inhibitor program for Alzheimer’s disease and tauopathies is partnered with Takeda; separate discovery programs target amyloid-beta aggregation, TDP protein aggregation in ALS and frontotemporal dementia, and mutant p53 aggregation in cancer.
